Toward Revision of the 'Best Practice for Diabetic Patients on Hemodialysis 2012'

Diabetic nephropathy is the leading cause of dialysis therapy worldwide. The number of diabetes patients on dialysis in clinical settings has been increasing in Japan. In 2013, the Japanese Society for Dialysis Therapy (JSDT) published the "Best Practice for Diabetic Patients on Hemodialysis 20...

Full description

Saved in:
Bibliographic Details
Main Authors: Masanori Abe (Author), Tomomi Matsuoka (Author), Shunsuke Kawamoto (Author), Kota Miyasato (Author), Hiroki Kobayashi (Author)
Format: Book
Published: MDPI AG, 2022-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ce3ab0ee5c2945f4b15bb6c8a8c3f412
042 |a dc 
100 1 0 |a Masanori Abe  |e author 
700 1 0 |a Tomomi Matsuoka  |e author 
700 1 0 |a Shunsuke Kawamoto  |e author 
700 1 0 |a Kota Miyasato  |e author 
700 1 0 |a Hiroki Kobayashi  |e author 
245 0 0 |a Toward Revision of the 'Best Practice for Diabetic Patients on Hemodialysis 2012' 
260 |b MDPI AG,   |c 2022-10-01T00:00:00Z. 
500 |a 10.3390/kidneydial2040045 
500 |a 2673-8236 
520 |a Diabetic nephropathy is the leading cause of dialysis therapy worldwide. The number of diabetes patients on dialysis in clinical settings has been increasing in Japan. In 2013, the Japanese Society for Dialysis Therapy (JSDT) published the "Best Practice for Diabetic Patients on Hemodialysis 2012". While glycated hemoglobin (HbA1c) is used mainly as a glycemic control index for dialysis patients overseas, Japan is the first country in the world to use glycated albumin (GA) for assessment. According to a survey conducted by the JSDT in 2018, the number of facilities measuring only HbA1c has decreased compared with 2013, while the number of facilities measuring GA or both has significantly increased. Ten years have passed since the publication of the first edition of the guidelines, and several clinical studies regarding the GA value and mortality of dialysis patients have been reported. In addition, novel antidiabetic agents have appeared, and continuous glucose monitoring of dialysis patients has been adopted. On the other hand, Japanese dialysis patients are rapidly aging, and the proportion of patients with malnutrition is increasing. Therefore, there is great variation among diabetes patients on dialysis with respect to their backgrounds and characteristics. This review covers the indices and targets of glycemic control, the treatment of hyperglycemia, and diet recommendations for dialysis patients with diabetes. 
546 |a EN 
690 |a antidiabetic agents 
690 |a burnt-out diabetes 
690 |a continuous glucose monitoring 
690 |a diabetes mellitus 
690 |a dialysis 
690 |a glycated albumin 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Kidney and Dialysis, Vol 2, Iss 4, Pp 495-511 (2022) 
787 0 |n https://www.mdpi.com/2673-8236/2/4/45 
787 0 |n https://doaj.org/toc/2673-8236 
856 4 1 |u https://doaj.org/article/ce3ab0ee5c2945f4b15bb6c8a8c3f412  |z Connect to this object online.